Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ruxolitinib continuous therapy · 1 trial · 1 indication
Compare to event free survival of patients at 3 years after allogeneic SCT and in Ruxolitinib continuous therapy in patients without a suitable donor
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | Treatment with Allogeneic Stem cell Transplantation after 3 months of Ruxolitinib induction therapy |
| Arm B | ACTIVE_COMPARATOR | Treatment with Ruxolitinib continuous therapy |
| Name | Type | Description |
|---|---|---|
| Allogeneic stem cell transplantation | PROCEDURE | - |
| Ruxolitinib continuous therapy | DRUG | - |
Inclusion Criteria: 1. Symptomatic primary myelofibrosis or myelofibrosis post polycythaemia vera or essential thrombocythemia stage intermediate 2- or high-risk according to IPSS or DIPSS \[46\] or intermediate 1-risk with high risk cytogenetics, other than normal karyotype, sole del 20q, del 13q,...
Ruxolitinib continuous therapy is used for bone marrow fibrosis, a condition also known as myelofibrosis. It is being studied as a treatment option for patients with this disease, with the goal of managing symptoms and potentially improving outcomes.
Ruxolitinib continuous therapy is being developed by Novartis AG, a global healthcare company. Novartis is conducting clinical trials to evaluate the safety and efficacy of this treatment for bone marrow fibrosis.
Ruxolitinib continuous therapy is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is still being studied in clinical trials to determine its safety and effectiveness.
Ruxolitinib continuous therapy is being evaluated in a Phase 2 clinical trial with the identifier NCT03333187. This trial is comparing ruxolitinib continuous therapy to allogeneic stem cell transplantation in patients with myelofibrosis, based on donor availability. The study is active but not recruiting participants.
Ruxolitinib continuous therapy works by targeting kinases, as it belongs to the -tinib class of kinase inhibitors. By inhibiting these enzymes, it aims to reduce the abnormal cell signaling that drives bone marrow fibrosis, potentially slowing disease progression and alleviating symptoms.
Ruxolitinib continuous therapy is a specific treatment regimen involving ruxolitinib, a JAK inhibitor. While the active ingredient is ruxolitinib, the continuous therapy approach refers to its ongoing administration, as opposed to intermittent dosing. This regimen is being studied specifically for bone marrow fibrosis.